Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

Ferring: PR agency sent unapproved, misleading Firmagon copy to a patient organisation (AUTH/2257/8/09)

Ferring admitted its PR agency sent uncertified, edited Firmagon copy to a patient organisation. The website content omitted…

8 Mar 2026

Pfizer: outdated menopause patient website implied oestrogen-only HRT reduced breast cancer risk (AUTH/2305/3/10)

A Wyeth-sponsored patient website used 2004 US WHI data and prominent β€œ-6” graphics implying oestrogen-only HRT protected against…

8 Mar 2026

Bristol-Myers Squibb & Pfizer: Eliquis HCP website omitted SSRI/SNRI bleeding-risk caution (AUTH/3155/2/19, AUTH/3156/2/19)

Eliquis HCP website listed NSAID/aspirin caution but omitted similar SSRI/SNRI cautions added to the updated SmPC. Panel found…

8 Mar 2026

AUTH/2380/1/11: Merz Pharma v Allergan β€” β€œNo set dose ratio” claim on Botox exhibition panel (No breach)

Merz challenged Allergan’s National Stroke Forum panel claiming β€œNo set dose ratio has been established between BoNT-A formulations”.…

8 Mar 2026

AUTH/3075/9/18: Director v Lundbeck β€” Clinical trial disclosure (outwith scope; no breach)

PMCPA case AUTH/3075/9/18 (Director v Lundbeck) concerned clinical trial disclosure but was ruled outwith the scope of the…

8 Mar 2026

Roche voluntary admission: Perjeta launch mailing sent before marketing authorisation and before final certification (AUTH/2582/2/13)

Roche admitted an uncertified Perjeta promotional mailing was sent to UK HCPs before marketing authorisation. PMCPA ruled breaches…

8 Mar 2026

AUTH/2600/4/13: Novo Nordisk v Sanofi – Lyxumia β€˜only once-daily prandial GLP‑1’ and other claims ruled misleading/exaggerated

Sanofi’s Lyxumia materials claimed it was the β€œonly once-daily prandial GLP‑1”, plus broad benefit and β€œstrong evidence” statements.…

8 Mar 2026

Boehringer Ingelheim breached Clauses 7.2 and 7.8 over unclear simulated dosing graph on congress stand (Pradaxa)

A congress-stand presentation included a dosing/missed-dose graph that wasn’t clearly labelled as simulated or properly attributed. The Panel…

8 Mar 2026

AUTH/2839/4/16: Anonymous v Merck Sharp & Dohme β€” Diabetes nurses study day sponsorship (No breach)

Anonymous complaint alleged MSD funded speakers and effectively ran a diabetes nurses study day without clear disclosure. Panel…

8 Mar 2026

Bayer: delayed disclosure of Phase I Xofigo trial results (AUTH/2908/11/16)

PMCPA found Bayer failed to post Phase I Xofigo trial results within the required 12 months after first…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training